Highlights•New therapies for infections caused by positive-strand RNA viruses are
needed.•Novel nucleoside and nucleotide analogs that inhibit HCV have been …

Chronic hepatitis C virus (HCV) infection is a global health problem. This chapter describes
the pharmacological profile and chemical syntheses of sofosbuvir. HCV specifically infects …

Ribonucleoside analog inhibitors (rNAI) target the hepatitis C virus (HCV) RNA-dependent
RNA polymerase nonstructural protein 5B (NS5B) and cause RNA chain termination. Here …

The treatment of viral infections remains challenging, in particular in the face of emerging
pathogens. Broad-spectrum antiviral drugs could potentially be used as a first line of …

Nowadays, a large number of people in the world are suffering from chronic Hepatitis C.
HCV NS5B polymerase conserved across the identified 7 HCV genotypes is considered to …

Hepatitis C virus (HCV), a causative agent for non-A and non-B hepatitis, has infected
approximately 3% of world's population. The current treatment option of ribavirin in …

In the world, approximately 130 to 170 million people are chronically infected with hepatitis
C virus (HCV) and it is estimated that more than 350,000 people die from this infection each …

More than 20 years after the identification of the hepatitis C virus (HCV) as a novel human
pathogen, the only approved treatment remains a combination of pegylated interferon-α and …

The HCV NS3 protease and NS5B polymerase play essential roles in the replication of the
hepatitis C virus (HCV). Following the successful paradigm established for HIV protease and …

Ribonucleotide analog inhibitors of the RNA-dependent RNA polymerase of hepatitis C
virus (HCV) represent one of the most exciting recent developments in HCV antiviral …